HERALD of North-Western State Medical University named after I.I. MechnikovHERALD of North-Western State Medical University named after I.I. Mechnikov2618-71162618-9704Eco-Vector850510.17816/mechnikov20157349-53Research ArticleEFFECT OF DIFFERENT TYPES OF LEUKOCYTE FILTERSON ERYTHROCYTE DONOR BLOOD PRODUCTS AT THEY PRODUCTIONSTAGE LEUKODEPLETIONBelyaevA E-MironenkoA N-PlatonovS M-City hospital №15, Saint-Petersburg1509201573495330032018Copyright © 2015, Belyaev A.E., Mironenko A.N., Platonov S.M.2015To evaluate the side effects of “production” leukofilters (LF) on filtering blood components, in particular - determine the degree of loss of hemoglobin at leykodepletion (LD) of erythrocyte blood components with various types of LF. The study of this parameter is necessary for determining reasonable criteria for selecting the type LF for everyday work in the production of red blood cell suspension (RBC’S), which would be most consistent with the concept of the “ideal”. Materials and Methods: Blood systems «Leukotrap RCPL» (production of «Pall Medical», USA) with integrated LF and «Demotec» (production of «Demophorius», Cyprus), which fluster LF “Leykosep» (production Company NLP «Interoko», Russia) were used for collection of donor blood. Results and discussion: 22 samples of leukodepleted RBC’S with LF “Leykosep” and 20 samples of RBC’S after LF «Pall» were examined for. Prior to the LD groups were quite comparable. The process of executing the LD leads to a significant reduction in the volume of the container contents and, accordingly, the loss of hemoglobin in the system with a reduction of its content in a dose of RBC’S. However, indicators of volume loss and reduction of hemoglobin in the “Interoko” group were significantly greater than in the group «Pall», which appear to be associated with the design of the LF. Accordingly, in the group “Interoko” amount of hemoglobin per dose of RBC’S was significantly less than in the group «Pall». At the same time revealed the difference between the groups in hemoglobin concentration after LD was on the damage trend without reaching statistical significance (p = 0.053), which may indicate an insufficient value of groups. However, indicators of hemoglobin concentration were within adequate values (N 40 g / dose) to meet the requirements of Technical regulations. Conclusions: Given the increasing number of proposals on the market LF existing assessment criteria (subjective convenience for staff, the producer price) becomes clearly insufficient, moreover it turns out that the use of different types of systems at least makes it necessary to clarify the accounting for losses of erythrocyte blood products in the LF. The study makes it clear that the manufacturer’s instructions to the LF and work instructions for the LD of erythrocyte blood components should include additional criteria - a loss of volume in the LF, which entails a significant reduction in hemoglobin content.Leukocyte filterleukodepletionerythrocyte blood componentsdonor bloodhemo- globin lossлейкоцитарный фильтрлейкодеплецияэритроцитные компоненты кровидонорская кровьпотери гемоглобина[Жибурт Е.Б., Голубева А.В., Мартынова М.В. Неблагоприятные эффекты, связанные с лейкоцитами, при гемотрансфузиях в хирургии // Вестник хирургии им. И.И. Грекова. 2001. №6. С.35-42.][Колосков А.В. Иммунные негемолитические реакции и осложнения гемотрансфузий // Гематология и трансфузиология. 2004. Т.49. №3. С.35-42.][Кузнецова Ю.В. Обзор научной литературы по проблеме удаления лейкоцитов из донорской плазмы // Трансфузиология. 2005. №2. С.108-114.][Максимов В.А. Инфекционная и антиагрегационная безопасность крови и ее компонентов // Главврач. Ежемесячный научно-практический журнал. 2008. №11. С.45-50.][Постановление Правительства РФ от 26 января 2010 г. № 29 «Об утверждении технического регламента о требованиях безопасности крови, ее продуктов, кровезамещающих растворов и технических средств, используемых в трансфузионно-инфузионной терапии» // Российская газета. 29.01.2010 г.][Суханов Ю.С., Максимов В.А. Лейкофильтрация и карантинизация плазмы донорской крови // Вестник службы крови России. 2003. №3. С.12-14.][Техническое руководство Американской Ассоциации Банков Крови // пер. с англ. Милан: Европейская школа трансфузионной медицины. 2000. С 611-612.][Blajchman M.A.,Vamvakas E.C. The Continuing Risk of Transfusion-Transmitted Infections // The N. Eng. J. of Med. 2006. V.355 (13). Р.1303-1305.][Dodd R.Y. Current Risk for Transfusion-Transmitted Infections // Curr. Opin. Hematol. 2007. V.14 (6). Р.671-676.]